Jamieson Wellness Inc. Announces Key Development in China Growth Strategy

Company appoints Shanghai-based consultant Mei Ye to its Board of Directors;

Builds on success story in Chinese market

Jamieson Wellness Inc. ("Jamieson Wellness" or the "Company") (TSX: JWEL) today reinforced its advancements in the world's second-largest vitamin market and announced the appointment of Shanghai-based Mei Ye to its Board of Directors, a key milestone in the Company's growth strategy in China. China is the Company's largest international market and a key driver of the Company's international revenue growth, which has more than quadrupled since 2014.

"We have had great success in China to date, and it is time to strengthen our team in this very important market," said David Williams, Chair of the Board of Directors of Jamieson Wellness. "We are pleased that Mei Ye has joined us on the Board of Directors, effective today. Her expertise in assisting companies with their China entry and growth strategies will be a huge asset to Jamieson Wellness as we continue to build on our accomplishments in the Chinese market."

Mei Ye is an independent corporate director and international business advisor, based in Shanghai. She is a senior advisor to McKinsey & Company, and a former management consultant and strategist with more than 25 years' experience in a variety of industries including consumer goods and retail. She currently serves on the board of Bekaert, a public company in steel cord transformation and coating technology in Belgium, and previously served as a director of the Shenwan Hongyuan Group, a portfolio company of China Investment Corporation, and as a director of leading securities company Shenyin & Wanguo.

"I am honoured to join a company with a nearly hundred-year history of improving the world's health and wellness, and excited for its potential in producing the safest, highest-quality natural health products for China's market," said Ms. Ye. "I am confident that Jamieson Wellness can help Chinese consumers make the right choices to proactively manage their health."

Jamieson Wellness currently has a three-pronged strategy in China delivering growth in cross border ecommerce, domestic retail and e-commerce, and holding a category leadership position with its international club partner. The Company offers more than 175 branded skus on cross border ecommerce, which is the fastest growing segment of the Chinese market. Its domestic retail business is experiencing strong double-digit growth with expanding distribution and store listings based on an increasing number of product registrations and existing product offerings available to domestic customers. The Company has more than 20 products in distribution in its international club partner's entry into the Shanghai market, and expects to grow with the partner's Chinese expansion plans.

The Company's operations in China include general management, sales, finance, procurement, regulatory and quality professionals based out of the Company's Shanghai office (Jamieson Shanghai Health Products Ltd.), and a distribution agreement with a Chinese partner, which the Company has the option to acquire at the end of the contract term. With the current distribution agreement expiring in 2022, the Company is considering a more direct approach to executing growth aspirations in all channels in China. Investments in marketing will continue to grow to increase trial and awareness and further develop the Company's understanding of the Chinese consumer.

"China is the second-largest vitamin market in the world, with growth outpacing the global industry average," said Mike Pilato, President and CEO of Jamieson Wellness. "We firmly believe the opportunities in this market will be transformational for our business, and we continue to focus on the Chinese consumer, expand our product offerings, and make strategic investments to continue to drive our growth. I look forward to working closely with Mei, the Board, and our management team as we enter our next phase of growth by further developing our China-based capabilities and taking a more hands-on approach to building scale in this priority market."

About Jamieson Wellness

Jamieson Wellness is dedicated to improving the world's health and wellness with its portfolio of innovative natural health brands. Established in 1922, Jamieson is the Company's heritage brand and Canada's #1 consumer health brand. Jamieson Wellness manufactures and markets sports nutrition products and specialty supplements under its Progressive, Precision and Iron Vegan brands. The Company also markets Smart Solutions, the #1 women's natural health focused brand in Canada. For more information please visit jamiesonwellness.com.

Jamieson Wellness' head office is located at 1 Adelaide Street East Suite 2200, Toronto, Ontario, Canada.

Forward-Looking Information

This press release may contain forward-looking information within the meaning of applicable securities legislation. Such information includes, but is not limited to, statements related to the Company's anticipated results and its outlook for its 2021 revenue, adjusted EBITDA and adjusted diluted earnings per share. Words such as "expect", "anticipate", "intend", "may", "will", "estimate", "believe", and variations of such words and similar expressions are intended to identify such forward-looking information. This information reflects the Company's current expectations regarding future events. Forward-looking information is based on a number of assumptions and is subject to a number of risks and uncertainties, many of which are beyond the Company's control that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking information. Such risks and uncertainties include, but are not limited to, the factors discussed under "Risk Factors" in the Company's Annual Information Form dated March 30, 2021 and under the "Risk Factors" section in the Company's MD&A dated May 5, 2021. This information is based on the Company's reasonable assumptions and beliefs in light of the information currently available to it and the statements are made as of the date of this press release. The Company does not undertake any obligation to update such forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable law or regulatory authority.

The Company cautions that the list of risk factors and uncertainties is not exhaustive and other factors could also adversely affect the Company's results. Readers are urged to consider the risks, uncertainties and assumptions associated with these statements carefully in evaluating the forward-looking information and are cautioned not to place undue reliance on such information. See "Forward-looking Information" and "Risk Factors" within the Company's MD&A for a discussion of the uncertainties, risks and assumptions associated with these statements.

Investor and Media Contact Information:  
Jamieson Wellness
Ruth Winker
416-705-5437
rwinker@jamiesonlabs.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)
Medicine capsule showing active ingredients.

5 Biggest Pharma Stocks in 2024

The pharmaceutical industry is a major player in the overall life science sector, responsible for developing and manufacturing the majority of prescription drugs.

Companies in this space are constantly researching and creating innovative treatments for various medical conditions. In recent years, there has been a particular focus on developing new treatments for diabetes, weight loss and cancer.

With the pharmaceutical sector projected to reach a staggering US$1.6 trillion in total revenue by 2028, there is an opportunity for investors to gain exposure to the growth potential of this industry while also benefiting from the diversification and stability provided by established companies.

Keep reading...Show less

PTC Therapeutics Enters into a Global License and Collaboration Agreement with Novartis for PTC518 Huntington's Disease Program

- PTC to receive $1.0B in cash at closing -
  - PTC is eligible to receive up to $1.9B in development, regulatory and sales milestones -
  - PTC to share profits in the U.S. and tiered double-digit royalties on ex-U.S. net sales -
  - Novartis will assume global development, manufacturing and commercial responsibilities following completion of placebo-controlled portion of ongoing PIVOT-HD study -
  - PTC will host a conference call on Dec. 2, 2024 , at 8:30 am EST -

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today the signing of an exclusive global license and collaboration agreement with Novartis Pharmaceuticals Corporation, a subsidiary of Novartis AG (NYSE: NVS), for its PTC518 Huntington's disease program, which includes related molecules. Under the agreement, PTC will receive an upfront payment of $1.0 billion up to $1.9 billion in development, regulatory and sales milestones, a profit share in the U.S., and double-digit tiered royalties on ex-U.S. sales.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Ratio Enters License and Collaboration Agreement with Novartis for SSTR2-targeting Radiotherapeutic Candidate

Ratio to receive upfront, and potential milestones and tiered royalty payments

Ratio Therapeutics Inc. ( Ratio ), a pharmaceutical company employing innovative technologies to develop best-in-class radiopharmaceuticals for cancer treatment and monitoring, entered today into an exclusive worldwide license and collaboration agreement with Novartis Pharma AG, a subsidiary of Novartis AG (NYSE: NVS). The collaboration leverages Ratio's radioligand therapy discovery and development expertise as well as its technology platforms for the development of a Somatostatin Receptor 2 (SSTR2) radiotherapeutic candidate for cancer.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Blank pill bottle spilling a variety of pharmaceutical pills and capsules.

5 Biggest Pharmaceutical ETFs in 2024

The global pharmaceutical market reached a total value of US$1.6 trillion in 2023, according to Statista, up significantly from the US$888 billion seen just over a decade earlier in 2010.

Experienced and novice investors alike may want to consider pharmaceutical exchange-traded funds (ETFs) as a way to gain exposure to the top pharma companies. Like all ETFs, pharmaceutical ETFs are a good option for those who want to trade a set of assets in the pharmaceutical industry instead of focusing solely on individual pharmaceutical stocks.

The main advantage of a pharmaceutical ETF is the fact that it can provide exposure to an overarching sector, but still trades like a stock. Pharma ETFs also offer less market volatility and lower fees and expenses.

Keep reading...Show less
Pill spelling "big pharma."

Big Pharma Stocks Eli Lilly, AbbVie and Pfizer Share Q3 Results

Major pharmaceutical players Eli Lilly (NYSE:LLY), AbbVie (NYSE:ABBV) and Pfizer (NYSE:PFE) reported mixed Q3 results, with each company facing distinct market forces, ranging from supply issues to financial constraints.

In its latest quarterly report, released on Wednesday (October 30), Eli Lilly missed on sales expectations for Zepbound, its popular weight-loss drug, and Mounjaro, its diabetes medication. Despite growing US demand for these products, supply chain management issues impacted the company’s ability to meet Wall Street's expectations.

According to Reuters, Eli Lilly dropped 8 percent on the news, reducing its market valuation by nearly US$70 billion.

Keep reading...Show less
Canada maple leaves on left and pharmaceutical pills in red and blue on right.

4 Best-performing Canadian Pharma Stocks of 2024

From established players to up-and-coming firms, Canada's pharmaceutical company is diverse and dynamic.

Canadian pharma companies are working to discover and develop major innovations amidst an increasingly competitive global landscape. Rising technologies such as artificial intelligence are playing a role in the landscape as well.

Here the Investing News Network lists the top Canadian pharma stocks on the TSX, TSXV and CSE by year-to-date gains. All data was compiled on October 28, 2024, using TradingView’s stock screener, and the companies considered had market caps above C$10 million at that time. Read on to learn about what's been driving their share prices.

Keep reading...Show less

Latest Press Releases

Related News

×